Vivendo Pharma

Executive Summary

Vivendo Pharma is a Swiss pharmaceutical consulting company that specializes in licensing out regulatory dossiers and intellectual property (IP) for biosimilars, generics, and innovative formulations. Founded in 2018, the company provides end-to-end services from dossier development to regulatory approval, acting as a partner for distributors and manufacturers. It leverages a network of scientific experts to support clients, primarily in emerging markets, without marketing finished drug products. The asset-light business model positions Vivendo to benefit from the growing global demand for affordable biosimilars and generics. However, as a private company with limited financial disclosure, its valuation and revenue trajectory remain opaque. The company's success hinges on securing licensing agreements and navigating regulatory hurdles across jurisdictions. Given the niche but defensible strategy and increasing market tailwinds for biosimilars, Vivendo Pharma presents a moderate but promising opportunity.

Upcoming Catalysts (preview)

• Q3 2026Partnership with a major generic manufacturer for licensing of a biosimilar dossier40% success
• Q3 2026Regulatory approval of a key biosimilar dossier by EMA or Swissmedic50% success
• Q1 2027Expansion into oncology biosimilars with new IP acquisitions or collaborations30% success